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Neurobiology of Disease
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Channel Contributes to -Amyloid Oligomer-Related
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In Alzheimer’s disease, accumulation of soluble oligomers of -amyloid peptide is known to be highly toxic, causing disturbances in
synaptic activity and neuronal death. Multiple studies relate these effects to increased oxidative stress and aberrant activity of calcium-
permeable cation channels leading to calcium imbalance. The transient receptor potential melastatin 2 (TRPM2) channel, a Ca2-
permeable nonselective cation channel activated by oxidative stress, has been implicated in neurodegenerative diseases, and more
recently in amyloid-induced toxicity. Here we show that the function of TRPM2 is augmented by treatment of cultured neurons with
-amyloid oligomers. Aged APP/PS1 Alzheimer’s mouse model showed increased levels of endoplasmic reticulum stress markers,
protein disulfide isomerase and phosphorylated eukaryotic initiation factor 2, as well as decreased levels of the presynaptic marker
synaptophysin. Elimination of TRPM2 in APP/PS1 mice corrected these abnormal responses without affecting plaque burden. These
effects of TRPM2 seem to be selective for -amyloid toxicity, as ER stress responses to thapsigargin or tunicamycin in TRPM2/
neurons was identical to that of wild-type neurons. Moreover, reduced microglial activation was observed in TRPM2//APP/PS1
hippocampus compared with APP/PS1 mice. In addition, age-dependent spatial memory deficits in APP/PS1 mice were reversed in
TRPM2//APP/PS1 mice. These results reveal the importance of TRPM2 for -amyloid neuronal toxicity, suggesting that TRPM2
activity could be potentially targeted to improve outcomes in Alzheimer’s disease.
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Introduction
InAlzheimer’sdisease (AD), aprogressivebiochemical cascade lead-
ing to neuronal dysfunction takes place many years before the ap-
pearanceof cognitivedeficits (Selkoe, 2011).These alterationsderive
at least in part from the accumulation of -amyloid peptides (A)
whose toxicity depends on its interactions with distinct cell surface
proteins. These include, but are not limited to, the prion protein
(Laure´n et al., 2009;Caetano et al., 2011;Ostapchenko et al., 2013b),
NMDAR (Snyder et al., 2005; Decker et al., 2010; Malinow, 2012;
You et al., 2012), mGluR5 (Renner et al., 2010), and 7 nicotinic
acetylcholine receptors (7nAChRs) (Wang et al., 2000). Although
precise mechanisms of toxicity remain unknown, dysregulation of
Significance Statement
Transient receptor potential melastatin 2 (TRPM2) is an oxidative stress sensing calcium-permeable channel that is thought to
contribute to calcium dysregulation associated with neurodegenerative diseases, including Alzheimer’s disease. Here we show
that oligomeric -amyloid, the toxic peptide in Alzheimer’s disease, facilitates TRPM2 channel activation. In mice designed to
model Alzheimer’s disease, genetic elimination of TRPM2 normalized deficits in synaptic markers in aged mice. Moreover, the
absence of TRPM2 improved age-dependent spatial memory deficits observed in Alzheimer’s mice. Our results reveal the impor-
tance of TRPM2 for neuronal toxicity andmemory impairments in anAlzheimer’smousemodel and suggest that TRPM2 could be
targeted for the development of therapeutic agents effective in the treatment of dementia.
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Ca2 homeostasis is widely accepted as being intimately associated
with A toxicity (LaFerla, 2002; Mattson, 2004). In light of the
marked toxicity of A toward glutamate synapses (Lambert et al.,
1998;Walsh et al., 2002; Lacor et al., 2007; Laure´n et al., 2009;Ma et
al., 2009; Ferreira and Klein, 2011), one particularly attractive can-
didate mechanism contributing to Ca2 dysregulation in AD is via
NMDARs (De Felice et al., 2007). However, block of NMDARs as a
therapeutic avenue is problematic as this can impair learning
and memory (Newcomer et al., 1999; Rammsayer, 2001), cause
psychotic-like symptoms in patients (Lahti et al., 1995; Breier et al.,
1997; Newcomer et al., 1999), and exacerbate neurodegeneration
(Ikonomidou et al., 2000). Identifying secondary sources of Ca2
entry, recruited downstream of aberrant NMDAR activation, may
provide attractive alternative targets for novel AD therapeutics.
Transient receptor potential melastatin 2 (TRPM2) is a Ca2-
permeable nonselective cation channel most highly expressed in
the CNS (Fonfria et al., 2006a; Olah et al., 2009; Bai and Lipski,
2010). Notably, TRPM2 is reported to modulate neuronal vul-
nerability to ischemia (Bai and Lipski, 2010; Alim et al., 2013),
and a variant of TRPM2 has been linked to neurodegenerative
diseases (Hermosura et al., 2008). Functionally, TRPM2 channel
opening is coupled to oxidative stress via the production of ADP-
ribose (ADPR), an intracellular TRPM2 agonist (Knowles et al.,
2013).However, ADPR alone is insufficient to gate TRPM2 chan-
nels rather channel activation is contingent on the binding of
Ca2 to an intracellular channel domain (Tong et al., 2006). In
this regard, we recently showed that TRPM2 channels are inti-
mately coupled to NMDARs via Ca2 influx (Olah et al., 2009)
and are necessary for the induction of NMDAR-dependent long-
term depression (Xie et al., 2011).
Here we show that A oligomers (AOs) augment TRPM2 cur-
rents in cultured neurons. Moreover, the absence of TRPM2 de-
creases endoplasmic reticulum (ER) stress and abnormalmicroglial
activation in TRPM2//APP/PS1 mice, without affecting plaque
burden. Critically, elimination of TRPM2 rescues cognitive deficits
in agedTRPM2//APP/PS1mice. Our results reveal an important
contributionof abnormalTRPM2activation to the cognitivedeficits
observed in aged ADmodel mice and suggest that this channel rep-
resents a new therapeutic target in AD.
Materials andMethods
Animals. TRPM2-null mice (TRPM2/) were generated in a C57BL/6J
backgroundasdescribedpreviously (Yamamoto et al., 2008).Wild-type and
TRPM2/mice were derived from heterozygousmating. Genotyping was
performed as previously described (Yamamoto et al., 2008). The APP/PS1
mouse model of AD, carrying the genes of human APP-Swedish mutation
and theE9mutation of the humanpresenilin 1 (Jankowsky et al., 2003), in
a C57BL/6J background was obtained from The Jackson Laboratory (stock
#005864). TRPM2/mice were crossed to APP/PS1 and the offspring in-
tercrossed to generate the desired genotypes. Mouse cohorts of desired ge-
notypes were generated and used longitudinally for behavioral analysis.
Randomized littermates were used for behavioral analysis. Only male mice
were used; and in all experiments, the experimenter was blind to the geno-
types. All animal experiments were conducted with approval from the Uni-
versity ofWesternOntarioAnimalUse Subcommittee (2008-127).Once the
mouse cohorts reached 20–24 months, they were killed and used for bio-
chemical and pathological analysis.
Electrophysiology. Primary cultured hippocampal neurons were derived
from time-pregnant CD1 or C57BL/6J or TRPM2/mice at E18 as previ-
ously described (Xie et al., 2011).Whole-cell voltage-clamp recordings were
performed fromneurons (14–21DIV) treated for24hwithcontrolmedium
or medium containing AOs (1 M), which is neurotoxic (Ostapchenko et
al., 2013b). AOswere prepared and routinely checked byWestern blotting
as described previously (Ostapchenko et al., 2013b). In short, synthetic
A(1–42) peptide (rPeptide) was monomerized in hexafluoroisopropanol,
reconstituted in DMSO, and diluted in PBS to a final concentration of 100
M. Oligomers were allowed to form for 24 h at 4°C and were then used for
experiments. For recording, the intracellular solution contained the follow-
ing (inmM): 150 cesium gluconate, 10HEPES, 2MgCl2, and 1ADPR. Stan-
dard extracellular solution contained the following (in mM): 140 NaCl, 5.4
KCl, 25HEPES, 33glucose, 2CaCl2, 0.003D-serine, and0.0002TTX.ADPR-
dependent TRPM2 currents were evoked in response to repeated applica-
tions of 100 M NMDA (10 s, repeated every 60 s) using a multibarrelled
rapid perfusion system (SF-77B; Warner Instruments). Once TRPM2 cur-
rents stabilized, a calcium free solution was applied to inactivate TRPM2
channels (total divalent concentration was maintained by replacing CaCl2
with equimolar BaCl2). Data were filtered at 2 kHz, digitized, and acquired
using pCLAMP and Axoscope software (Molecular Devices).
Real-time quantitative PCR. RNAs from WT and TRPM2/ hip-
pocampi (three for each genotype) were purified as described previously
(Ostapchenko et al., 2013a). To quantify expression levels of genes of
interest, RNA samples were amplified in real-time quantitative PCR us-
ing the following primers: Trpm2 (forward, CTGTCTCCGTCTCATG
CACA; reverse, AGACGTCCTTCATCATCCGC); Trpm7 (forward, TC
TACTTCTCTTCACTCGGTGC; reverse, TGTTCCTCCTTCAGATGG
CATT); GluN1 (forward, ACACAAGGATGCCCGTAGGA; reverse, TT
TTAGGGTCGGGCTCTGCT); GluN2A (forward, CATTGGGAGCG
GGTACATCTTT; reverse, TGGCTGCTCATCACCTCATTC); GluN2B
(forward, GAGCGCCAATCCGTGATGAA; reverse, TAGACAGAGGACT
CACGGCG);GluA2 (forward, GTGAGTCCTGGCATGGGAATG; reverse,
TATCGGATGCCTCTCACCACTT); Cav1.2 (forward, ACGTCAGCAAC
CTGTAGTCC; reverse, AGCTCTGAGGCTTATCCCGA); Chrna7 (for-
ward, TGGAGGACGAGAATTGGGGT; reverse, TGCCGGTGATGGGT
GTAAGA). As the reference gene, Pgk1 (forward, GTCGTGATGAGGG
TGGACTT; reverse, TTGGCTCCATTGTCCAAGCA)was used as it is con-
sistently expressed inmouse hippocampus (Boda et al., 2009).
Western blotting, ELISA, and immunohistochemistry.Mice were anes-
thetized using ketamine (100 mg/kg) and transcardially perfused with
0.9% saline. For each mouse, the cortex and hippocampus from one
hemibrain were used for ELISA and Western blotting analyses; the
other hemibrain was postfixed as described below and used for
immunostaining.
Forhippocampus fractionation, tissueswerehomogenized in50mMTris-
HCl, pH 7.2, 200 mM NaCl, 2 mM sodium EDTA, with protease inhibitor
cocktail III (Millipore), centrifuged at 100,000  g, and the supernatants
were used as the Tris-soluble fraction of the proteins. The sediments were
resuspended in radioimmunoprecipitation assay buffer (50 mM Tris-HCl,
pH 8, 150mMNaCl, 1%NP-40, 1% sodium deoxycholate, and 1% sodium
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dodecyl sulfate) containing protease inhibitor cocktail III (Millipore) and
phosphatase inhibitors 10mMNaFand0.5mMNa3VO4, followedby3cycles
(power 3) of sonication for 10 swith 1min intervals between the cycles using
Sonic Dismembrator M100 (Fisher Scientific) on ice. Samples were centri-
fugedat 16,000 g for 30min, and the supernatantswereusedas the cellular
fraction of the proteins. Remaining sediments were solubilized in 5 M
guanidine-HCl, 50mMHEPES, pH7.3, 5mMEDTA, followedby rotation at
room temperature for 3 h, and used as insoluble protein fraction. Protein
concentration was measured using the Bradford assay.
For Western blotting, a total of 30 g of each sample was resolved
by electrophoresis in SDS-polyacrylamide gels using 13.5% Tris-
tricine gels or 4%–12% PAGEr Gold precast gels (Lonza), followed by
a standard blotting procedure using anti-protein disulfide isomerase
(PDI) (1:1000, catalog #3501), anti-synaptophysin (1:2000, catalog
#5467, both Cell Signaling Technology), or anti -amyloid (6E10,
1:2000, Covance) antibodies.
ELISA was performed using the kit for human A(1–42) (catalog
#KHB3544, Invitrogen). Tris-soluble and insoluble fractions were diluted
30- and 500-fold in dilution buffer and the A(1–42) concentration was
measured using synthetic peptide as a standard.
For immunohistochemistry, hemibrains were postfixed for 48 h with
4% PFA in phosphate-buffered saline. Coronal sections (50 m) were
cut using a vibratome. Polyclonal anti-human A antibody (catalog
#44344, Invitrogen), anti-peIF2 (Ser51) antibody (catalog #9721, Cell
Signaling Technology), anti-Synaptophysin antibody (catalog #sc-9116,
Santa Cruz Biotechnology), and anti-Iba1 antibody (catalog #PA5-
27436, Thermo Fisher Scientific) were used on free-floating sections. A
was retrieved by boiling the sections in 10 mM sodium citrate buffer.
Nonspecific binding was prevented by incubation with 2% horse serum
(Invitrogen) and 2% BSA in TBS with 0.3% Triton X-100. Sections were
then processed for immunostaining by overnight incubation at 4°C in
the primary antibody (1:200) diluted in TBS. After rinsing twice in TBS,
sections were incubated for 2.5 h at 4°C with the secondary antibody
diluted in TBS containing 1% horse serum and 1% BSA, rinsed three
times and mounted.
For thioflavin S staining, sections were incubated in 0.25%KMnO4 for 5
min, rinsedwithwater, and treatedwith bleaching solution (1%Na2S2O5
1% axalic acid) for 2 min. After rinsing with water, sections were placed in
blockingsolution(1%NaOH0.9%H2O2) for30s,washed, and incubated
in 0.25% acetic acid for 5 s. Sections were then washed, placed on silanized
slides, and stainedwith1.25%thioflavinS solution in50%ethanol for5min.
Slices were rinsed once with 50% ethanol, twice with water, andmounted.
Mounted slices were imaged using a Zeiss LSM-510 confocal micro-
scope equipped with either 10/0.4 or 20/0.75 objectives. Image anal-
ysis was done using ImageJ software (National Institutes of Health).
ER stress in primary neuronal cultures and surface sensing of translation
(SUnSET) protein synthesis assay. ER stress in cultured hippocampal wild-
type and TRPM2/ neurons at 14–18 DIV was induced by treating them
with either 1 M thapsigargin or 3 g/ml tunicamycin and incubation for
18hat 37°C inCO2 atmosphere.Cellswere thenwashed two timeswithECF
containing the following (inmM): 140NaCl, 25HEPES, 5.4 KCl, 33 glucose,
2CaCl2, 1MgCl2, andproteins, extractedwith 2Laemmli buffer added to
each well (4% SDS, 20% glycerol, 10% 2-mercaptoethanol, 0.125 mM Tris
HCl, pH 6.8, 0.004% bromophenol blue). Lysates were collected and incu-
bated at 95°C for 5min before loading on a 12% SDS-PAGE gel at 20l per
lane. Proteins were transferred to BioTrace NT membrane (Pall Life Sci-
ence), followed by standard Western blotting with antibodies against
p-eIF2 (1:1,000), eIF2 (1:1000) (Cell SignalingTechnology, catalog#3398
and2103, respectively), andGRP78/BiP (1:300) (Abcam, catalog#ab21685).
All secondary antibodieswere fromJackson ImmunoResearchLaboratories.
Newly synthesized proteinwasmeasured following ER stress with thapsi-
gargin by using a modified SUnSET assay (Schmidt et al., 2009). Cultured
neurons from wild-type or TRPM2/mice (14 DIV) were treated with 1
M thapsigargin or were left untreated, and placed in the incubator for 18 h;
2g/mlpuromycinwas added toall culturewells and incubated for a further
2 h to allow for incorporation of puromycin into new proteins. Cells were
then washed in ECF and lysed in 2 Laemmli buffer. SDS-PAGE, transfer,
andWestern blottingwere done as described above. Anti-puromycin (clone
12D10, Millipore) was used at 1g/ml.
Elevated plus maze and locomotor activity. Anxiety-like behavior was
assessedusing the elevatedplusmaze test, performedasdescribedpreviously
(Martins-Silva et al., 2011). Sessions were recorded and analyzed using the
ANY-Maze software (Stoelting) to determine total time spent in the open
and closed arms. Spontaneous locomotor activity in a new environment, a
measure of exploratory behavior, was recorded using automated locomotor
boxes as described previously (Guzman et al., 2011).
Barnes maze. The Barnes maze consists of a white, circular platform (92
cm in diameter) with 20 equally spaced holes (5 cm in diameter; 7.5 cm
between holes), elevated 105 cm above the floor (San Diego Instruments).
Micewere trainedat3, 6, 9, 12, and15monthsof age,withall testsperformed
between 09:00 and 16:00 h as previously described (Martyn et al., 2012). For
each new acquisition phase, the location of the target hole was changed. To
test referencememory, a probe trial was conducted on the fifth day inwhich
the target hole was barred and the number of nose-pokes to eachmaze hole
was recorded. Path length, the number of hole-pokes before reaching the
target (errors), and latency to reach the barred target hole were also mea-
sured. Sessions were recorded and analyzed using the ANY-Maze software.
Results were expressed as number of target hole visits and preference of
target hole overothers (target hole visits /averagenontarget visits) during the
probe trial.
Morris water maze (MWM). The MWM was performed as previously
described (Martyn et al., 2012). Briefly,mice received 4 consecutive training
days, with four trials per day separated by 15 min inter test intervals. A
hiddenplatformwaskept inaconstant location in thecenterofonequadrant
of a 2-m-wide round pool. For each trial, mice were randomly placed at one
of the four equally spaced starting locations within the pool. Each trial con-
sisted of a swim followed by a 10 s platform sit. To assess spatial memory, a
probe trial was performed on the fifth day. For this trial, the platform was
removed from the pool and the mice were allowed to swim freely for 60 s.
Experiments were recorded using a video camera and analyzed using ANY-
Maze video tracking software (Stoelting).
Statistical analyses.Western blots and immunohistochemistry data were
quantified using ImageJ software (National Institutes of Health) and ana-
lyzed using one-way ANOVA with Tukey’s post hoc or by Student’s t test
using GraphPad Prism software. For behavioral studies, ANOVA followed
by an appropriate post hoc test was used to compare multiple groups, using
GraphPad Prism or SigmaStat software.
Results
A oligomer treatment sensitizes ADPR-dependent TRPM2
currents generated by repeated NMDAR stimulation
Wepreviously reported that repeated applications ofNMDA to cul-
tured hippocampal neurons initiate the development of large
ADPR-dependent TRPM2 currents (Olah et al., 2009; Belrose et al.,
2012). To investigate whether TRPM2 channel function can be
modulated by AOs, we treated cultured hippocampal neurons for
24 h with AOs, a procedure known to increase neuronal death
(Kudo et al., 2012; Ostapchenko et al., 2013b). As shown in Figure
1A, B, NMDA-induced TRPM2 currents were augmented by AO
treatment.
Decreased levels of ER stress in brains of APP/PS1mice
lacking TRPM2
To study the influence of TRPM2channels onAneuronal toxicity,
we crossed APP/PS1 mice (Jankowsky et al., 2003) to TRPM2/
mice (Yamamoto et al., 2008). The offspring were then intercrossed
to generate the four genotypes used in this study (WT, TRPM2/,
APP/PS1, and TRPM2//APP/PS1).
In AD patients and AD mouse models, increased protein mis-
folding leads to ER stress and the activation of the unfolded protein
response (Matus et al., 2011; Scheper et al., 2011; Hetz and
Mollereau, 2014). Among ER stress proteins, PDI has been found
increased in the brain of ADpatients (Kim et al., 2000; Andreu et al.,
2012). Using immunoblots, we tested whether expression of PDI is
changed in the hippocampus of 20- to 24-month-old APP/PS1 and
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TRPM2//APP/PS1mice compared withWT controls. Similar to
previous reports in AD patients, APP/PS1 mice showed increased
levels of PDI (Fig. 1C,D). In contrast, the levels of PDI in
TRPM2//APP/PS1mice were no different from that ofWT con-
trols or TRPM2/mice (Fig. 1C,D).
Increased phosphorylation of the eukaryotic initiation factor
2 (eIF2) at Ser51 in response to ER stress inhibits global pro-
tein translation and contributes to synaptic pathophysiology in
the APP/PS1 mouse model of AD (Yasuda et al., 2002; Ma et al.,
2013). We therefore tested whether the absence of TRPM2 could
prevent changes in eIF2 phosphorylation in neurons of APP/
PS1 mice. To specifically compare the response in neurons, we
used immunofluorescence and quantified the staining of neuron-
rich hippocampal areas. In areas CA1, CA2, and CA3 of the hip-
pocampus of APP/PS1 mice, pSer51-eIF2 immunoreactivity
was higher compared with wild-type controls (Fig. 1E,F). Con-
versely, in TRPM2//APP/PS1 mice, hippocampal pSer51-
eIF2 immunoreactivity was similar to the levels found in the
hippocampus of TRPM2/mice (Fig. 1E,F).
TRPM2/ neurons do not have altered ER stress responses
or major compensatory responses
To examine the possibility that ER stress responses in general are
altered in TRPM2/ neurons, the response to ER stressors,
thapsigargin (Tg) or tunicamycin (Tn), was determined bymon-
itoring the changes in the expression levels of pSer51-eIF2 and
Figure 1. TRPM2 is responsive to AOs and contributes to increased ER stress in APP/PS1 mice. A, Representative traces show that NMDA facilitated ADPR-induced TRPM2 currents evoked in
cultured hippocampal neurons from CD1 mice in the absence or presence of AOs. These could be inhibited by omitting Ca 2 from the extracellular recording solution. TRPM2 current amplitude
wasdeterminedas indicatedbybidirectional arrowspositionedbetween the stippled lines.B, Summarybar graphs show that treatmentwith1MAOs for 24h increases TRPM2current amplitude
and density. Data from at least five cells for each treatment were analyzed with Student’s t test. **p 0.01. C, D, Immunoblot analysis of PDI levels in hippocampal extracts. At least four brain
extracts obtained from each genotype were analyzed. E, F, Immunofluorescence analysis of phospho-eIF2(Ser51) (green) levels in CA1, CA2, and CA3 areas of mouse hippocampus.III-tubulin
(red) and Hoechst dye (blue) were used to label neurons and nuclei, respectively. At least four coronal slices from each mouse brain and at least three brains of each genotype were used for
immunostaining. *p 0.05 (one-way ANOVA followed by Tukey’s post hoc test). **p 0.01 (one-way ANOVA followed by Tukey’s post hoc test). ***p 0.001 (one-way ANOVA followed by
Tukey’s post hoc test). #p 0.05 when comparing pSER51WT levels to TRPM2/APP/PS1 levels. Scale bar, 90m.
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Grp78/BiP, an ER chaperone andmaster regulator of ER stress. In
cultured hippocampal neurons from both WT and TRPM2/,
Tg or Tn treatment resulted in increased levels of pSer51-eIF2
and Grp78/BiP. No difference in the ER stress response bet-
ween genotypes was observed (Fig.
2A–D). Consistent with the increased lev-
els of pSer51-eIF2 in response to ER
stress, general protein translation, deter-
mined using nonradioactive SUnSET, was
reduced by treatment with Tg. Again, no
difference in this responsewas observed in
the absence of TRPM2 compared with
control neurons (Fig. 2E,F).
To further examine whether the ab-
sence of TRPM2 can elicit compensatory
responses in transcripts that regulate
pathways related to Ca2-induced toxic-
ity, we used qRT-PCR. We tested the ex-
pression of genes previously linked to
NMDAR/AO excitotoxicity in the hip-
pocampus of controls and TRPM2/
mice. For NMDAR subunits, we limited
our analysis to GluN1, GluN2A, and
GluN2B, the most highly expressed sub-
types in the adult hippocampus and
cortex (Monyer et al., 1994).We alsomea-
sured transcript levels of the AMPAR sub-
unit GluA2, inclusion of which renders
AMPARs Ca2-impermeable, and of
genes implicated in Ca2 dysregulation in
AD (Demuro et al., 2010), including the
7 nicotinic acetylcholine receptor and
L-type voltage-gated Ca2 channels (CaV
1.2). Last, as TRPM7 and TRPM2 expres-
sion has previously been suggested to be
interdependent (Aarts et al., 2003), we
examine whether TRPM7 expression was
altered in TRPM2/ mice. qRT-PCR
analysis of hippocampal extracts from
WT and TRPM2/ mice confirmed the
absence of TRPM2 mRNA in TRPM2/
mice (Fig. 2G). There were no changes in
the hippocampal mRNA levels of NMDA
receptor subunits (i.e., GluN1, GluN2A,
and GluN2B), GluA2, 7 nicotinic acetyl-
choline receptor CaV 1.2, or TRPM7
(Fig. 2G).
Prevention of synapse loss in APP/PS1
mice lacking TRPM2
Given that synapse loss and decreased
levels of synaptic proteins are early cor-
relates of AD severity (Pozueta et al.,
2013), we compared the expression lev-
els of the synaptic marker synaptophy-
sin in the hippocampus of APP/PS1
mice with that of TRPM2//APP/PS1
mutants. Immunofluorescence analysis
showed that synaptophysin levels were
decreased in the hippocampus of APP/
PS1 mice compared with WT controls.
On the other hand, synaptophysin
staining in the hippocampus of
TRPM2//APP/PS1 mutants was similar to that observed for
WT controls (Fig. 3A–D). Likewise, labeling of synaptophysin
in the hippocampus of TRPM2/ was not different fromWT
controls (Fig. 3A–D). These results suggest that elimination of
Figure2. TRPM2/neurons do not have altered ER stress responses ormajor compensatory responses.A–D, Representative
immunoblots of wild-type (A) and TRPM2/ (B) primary hippocampal neuronal cultures, nontreated or treated with thapsi-
gargin (Tg) or tunicamysin (Tn) as described in Materials and Methods. Analysis of p(S51)-eIF2 (C) and GRP78/BiP (D) levels. At
least six samples were analyzed for each condition. For each treatment condition (Tg or Tn), data were analyzed with Student’s t
test. E, F, SUnSET assay of protein synthesis in control and thapsigargin-treated cultured hippocampal neurons. E, Representative
blots. F, Analysis of puromycin immunostainingwas done for three samples for each condition. Datawere analyzedwith Student’s
t test. G, qRT-PCR comparison of hippocampal mRNA levels of TRPM2, TRPM7, GluN1, GluN2A, GluN2B, GluA2, Cav 1.2, and
7NAChR in WT and TRPM2/ mice. Data were collected from three samples for each genotype, normalized by Pgk1 mRNA
levels, and analyzed with Student’s t test.
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TRPM2 prevents the decrease in synaptophysin levels ob-
served in the brains of 20- to 24-month-old APP/PS1 mice.
Decreased microglial activation in APP/PS1mice
lacking TRPM2
We tested whether the absence of TRPM2 affects microglial acti-
vation in APP/PS1 mice by measuring Iba1 immunostaining, a
marker of microglia. Our analysis shows that, while Iba1 immu-
noreactivity was increased in the hippocampus of APP/PS1 mice
compared with WT controls, there was no difference in Iba1
staining when comparing TRPM2//APP/PS1 mutants with
WT controls (Fig. 4A,B). These results suggest that, while brains
of APP/PS1 mice show increased microglial response, this re-
sponse is absent in the brains of TRPM2//APP/PS1 mutants.
Together, these data provide multiple lines of evidence demon-
strating that elimination of TRPM2 expression improves end-
points related to pathological hallmarks in APP/PS1 mice.
TRPM2 elimination does not change plaques or soluble A
peptides but slightly decreases the levels of small molecular
weight oligomers
It is possible that the absence of TRPM2 could influence amyloid
processing and accumulation, which may contribute to altered
levels of ER stress markers. Hence, we analyzed A(1–42) levels
in soluble, membrane-bound and insoluble amyloid plaque-
associated fractions of hippocampal proteins. We did not detect
any difference between APP/PS1 or TRPM2//APP/PS1 mu-
tants when comparing them for A(1–42) immunofluorescence
staining or thioflavin S-positive plaques (Fig. 5A,B). Similarly,
ELISA determination of A(1–42) content in insoluble and Tris-
soluble fractions from APP/PS1 and TRPM2//APP/PS1 hip-
pocampal samples showed no change (Fig. 5C,D). To further
investigate whether different oligomeric fractions of A peptides
may be affected by lack of TRPM2, we resolved low molecular
weight oligomers by Tris-tricine gel electrophoresis of hip-
pocampal lysates. These experiments revealed a decreased
amount of A trimers and tetramers in RIPA-soluble fractions of
TRPM2//APP/PS1 hippocampi comparedwithAPP/PS1mice
(Fig. 5E). As overall A peptides and amyloid plaques are not
affected by lack of TRPM2, the decreased levels of cell-associated
low molecular weight AOs detected in TRPM2//APP/PS1
mutants may reflect decreased cellular stress level compared with
APP/PS1mice. This may improve the turnover ofmisfolded pro-
teins and, therefore, cell-bound AOs.
Elimination of TRPM2 in APP/PS1mice does not change
age-related hypoactivity
To determine whether improved AD pathological hallmarks ob-
served in APP/PS1 mice lacking TRPM2 channels translates into
improved behavioral performance, we compared the perfor-
mance of TRPM2//APP/PS1 mutants with that of APP/PS1,
WT, and TRPM2/ controls. Importantly, the tests were per-
formed longitudinally in the same cohort of mice at different
time points, so that we could evaluate age-related progression of
behavior deficits.
As hypoactivity is frequently observed both in human AD
patients and transgenic mouse models of AD (Ferguson et al.,
2013; Iqbal et al., 2013), we investigated locomotor activity using
automated open field chambers. Locomotor activity was re-
corded at 3, 6, 9, 12, and 15 months of age. We detected no
difference in activity in the four genotypes until 12 months of
age (Fig. 6A). At 12–15 months of age, both APP/PS1 and
TRPM2//APP/PS1 mutants showed decreased locomotor ac-
tivity compared withWT controls andTRPM2/mice [Fig. 6A;
two-way ANOVA, significant main effect of APP/PS1 carriers:
F(1,33)  11.12, p  0.0021; no differences between noncarriers
(WT and TRPM2/): F(1,33)  0.9240, p  0.3438; and no in-
teraction]. These results suggest that the hypoactivity phenotype
was not affected by ablation of TRPM2 channels.
To test for anxiety behaviors, we performed the elevated plus-
maze task (Fig. 6B). Therewere no differences in the time spent in
the open arms among the four mouse genotypes (representative
result for 15-month-old mice, ANOVA, no effect of APP/PS1
F(1,38) 0.7546, p 0.3905; no differences between noncarriers:
F(1,38)  0.1139, p  0.7376; and no interaction). Hence, the
APP/PS1 transgenes did not affect anxiety-like behavior. More-
over, TRPM2 elimination did not affect anxiety-like behavior.
Elimination of TRPM2 in APP/PS1mice rescues spatial
memory deficits
To test whether loss of TRPM2 had any effect on cognitive defi-
cits in APP/PS1 mice, we used two spatial memory tests, the
Barnes maze and the MWM.We tested mice at 3, 6, 9, 12, and 15
months of age in the Barnes maze and at 12 and 15months in the
MWM. Similar to previous reports (Savonenko et al., 2005), our
Barnes maze analysis did not detect consistent spatial memory
deficits when APP/PS1 mice were compared with controls until
12 months of age (Fig. 7A–D). However, APP/PS1 mice showed
clear spatial deficits in the Barnes maze at 15 months of age (Fig.
7E,F). It is important to note that, because of the longitudinal
nature of the study, the same cohort of mice was tested in the
Figure 3. Levels of synaptophysin are rescued in brains of TRPM2//APP/PS1mice.A–D,
Immunofluorescence analysis of synaptophysin levels (green) in CA3 (A, B) and DG (C, D) areas
of mouse hippocampus. Hoechst dye (blue) was used to label nuclei. At least four coronal slices
from each mouse brain and at least 3 brains of each genotype were used for immunostaining.
**p 0.01 (one-way ANOVA followed by Tukey’s post hoc test). ***p 0.001 (one-way
ANOVA followed by Tukey’s post hoc test). Scale bars: A, 45m; C, 90m.
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Barnes maze at 5 different time points. Even though the location
of the target hole was changed between tests, analysis of latency
time to reach the target role suggests thatmice from all genotypes
seem to remember the “task rules” as they performedwell already
on the first day of training from 6 months up to 12 months (Fig.
7A,B). Probe trials at 12 months showed no differences among
genotypes for either the number of times mice visited the target
hole or the target role preference index (Fig. 7C,D). At 15months
of age, no differences were observed among genotypes in the
number of errors made before reaching the target hole (Fig. 7A),
but mice carrying the APP/PS1 transgenes presented longer la-
tencies to first visit the target hole than control mice [two-way
repeated-measures ANOVA, significant main effect of genotype:
F(3,119)  4.883, p  0.006, post hoc analysis showed significant
differences, p  0.05, when noncarriers (WT and TRPM2/)
were compared against carriers (TRPM2//APP/PS1 and
APP/PS1); Fig. 7B]. Considering that both APP/PS1 and
TRPM2//APP/PS1 mice showed decreased locomotor activity
at 15 months (Fig. 6A), the difference ob-
served in latency to visit the target hole is
more likely due to hypoactivity than to a
learning deficiency. Strikingly, 15-
month-old APP/PS1 mice made fewer
target hole visits than the other genotypes
during the probe trial (F(3,37) 18.49, p
0.0006, post hoc analysis showed signifi-
cant differences, p 0.05, when APP/PS1
mice were compared vs WT, TRPM2/,
and TRPM2//APP/PS1). In contrast,
TRPM2//APP/PS1mice made as many
visits to the target hole and preference in-
dex as WT or TRPM2/ mice (Fig.
7E,F). These results suggest that elimina-
tion of TRPM2 alleviates the spatial mem-
ory deficits in the Barnesmaze observed at
15 months in the AD mouse model.
Similar results were observed in
MWM task (Fig. 8). Analysis of escape
latency to the platform showed a de-
crease in the time to find the platform
over training day for all genotypes at 12
months (Fig. 8A; two-way repeated-
measures ANOVA, significant effect of
training day: F(3,126) 37.95, p 0.001)
and 15 months (Fig. 7E; two-way
repeated-measures ANOVA, significant
effect of training day: F(3,117)  11.55,
p  0.001). This suggests that all geno-
types were able to learn the task. Inter-
estingly, mice carrying the APP/PS1
transgenes showed longer latencies to
find the platform at both 12 months
(two-way repeated-measures ANOVA,
significant effect of genotype: F(3,126) 
3.632, p  0.0203, post hoc analysis
showed significant differences, p 0.05,
between WT and TRPM2/ compared
with TRPM2//APP/PS1 and APP/
PS1) and 15months (two-way repeated-
measures ANOVA, significant effect of
genotype: F(3,117)  4.167, p  0.0118,
post hoc analysis showed significant
differences, p  0.05, between WT
and TRPM2/ compared with TRPM2//APP/PS1 and
APP/PS1). Analysis of the distance traveled to find the target at
12 months (Fig. 7B) or 15 months (Fig. 7F ) indicated signifi-
cant main effects of genotype (12 months: two-way repeated-
measures ANOVA, F(3,126)  4.531, p  0.0077; 15 months:
two-way repeated-measures ANOVA, F(3,117)  4.167, p 
0.0118) and day (12 months: two-way repeated-measures
ANOVA, F(3,126)  25.90, p  0.0001; 15 months: two-way
repeated-measures ANOVA, F(3,117)  11.55, p  0.0001).
Overall, mice carrying the APP/PS1 transgenes, independent
of the presence or absence of TRPM2, exhibited increased path
lengths. However, at day 4, the performance of all genotypes
was identical both at 12- and 15-month old mice. Addition-
ally, swim speed analysis showed no differences in perfor-
mance among genotypes at 12 months (Fig. 8C; two-way
repeated-measures ANOVA, no differences in genotype:
F(3,123) 0.5156, p 0.6738) or 15 months (Fig. 8G; two-way
repeated-measures ANOVA, no differences in genotype:
Figure4. Decreasedmicroglial activation in brains of TRPM2//APP/PS1mice. Levels of activatedmicroglia in DG (A,B) area
of mouse hippocampus were analyzed by Iba1 immunostaining (red). Hoechst dye (blue) was used to label nuclei. At least four
coronal slices from eachmouse brain and at least 3 brains of each genotypewere used for immunostaining. **p 0.01 (one-way
ANOVA followed by Tukey’s post hoc test). ***p 0.001 (one-way ANOVA followed by Tukey’s post hoc test). Scale bar, 90m.
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F(3,117)  0.9244, p  0.4380), indicating that differences ob-
served in the MWM between mice expressing the APP/PS1
transgenes compared with those without it are not due to the
decreased physical activity in the pool. Together, these results
suggest that 12- and 15-month-old mice carrying the APP/PS1
transgenes showed difficulties learning the MWM spatial task
as they took longer than WT and TRPM2/ to learn the
location of the platform; however, the deficit did not seem to
be extensive, as it disappeared after repetitive training.
The MWM probe trial in 12-month-old mice showed no
significant differences among genotypes (Fig. 8D) and a sig-
nificant main effect of quadrant (F(3,140) 52.178, p 0.001).
Further analysis indicated that all genotypes spent more time
in the target quadrant than in any other quadrant (p 0.001,
for Target vs opposite, Target vs right, and Target vs left).
Analysis of the percentage of time searching in the target quad-
rant showed no differences in memory retention among the
four genotypes (F(3,35)  0.3544, p  0.7863). These results
indicate that there are no memory impairments in any of the
mouse groups at 12 months. At 15 months (Fig. 8H ), the
results showed that APP/PS1 mice spent significantly less time
in the target area than the other genotypes (F(3,39) 5.887, p
0.0020, post hoc analysis: p  0.05 vs TRPM2//APP/PS1,
WT, and TRPM2/), whereas TRPM2//APP/PS1 mice
performed similarly to the WT animals (p  0.05). These
results show that 15-month-old APP/PS1 mice were unable to
recall where the platform was located, and this spatial memory
deficit was rescued in TRPM2//APP/PS1 mice.
In conclusion, Barnes maze and MWM results indicate that
APP/PS1 mice present clear age-dependent spatial memory def-
icits and that elimination of TRPM2 channels ameliorates these
deficits.
Figure 5. Normal plaque load in brains of TRPM2//APP/PS1mice. A levels in mouse hippocampus. A, B, Brain slices were stained for plaques with anti-A(1– 42) IgG (A) and thioflavin S
(B). At least four coronal slices fromeachmouse brain and at least three brains of APP/PS1 and TRPM2//APP/PS1micewere used for each immunostaining experiment. C,D, Levels of A(1– 42)
of insoluble (C) and Tris-soluble (D) fractions of at least 6 hippocampi of APP/PS1 and TRPM2//APP/PS1 mice were analyzed by ELISA. E, Western blot analysis of intracellular and cell
membrane-bound fractions of hippocampus. The lower band corresponds to the trimers, and the upper band to the tetramers of A(1– 42). At least five extracts obtained fromeach genotypewere
analyzed. *p 0.05 (Student’s t test).
Figure 6. Elimination of TRPM2 in APP/PS1 mice does not change age-related hypoactivity
or anxiety. A, Exploratory activity in the open field test of 3- to 15-month-old mice. At 15
months, carriers of APP/PS1 transgenes show decreased locomotion compared with noncarri-
ers.B, Representative elevatedplusmazeexplorationof 15-month-oldmice. Bars represent the
percentage of time spent by the four genotypes in the Open Arm of themaze. *p 0.05. N for
WT 8–12, N for TRPM2/ 7–10, N for APP/PS1 10 or 11, N for TRPM2//APP/
PS1 10 or 11.
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Discussion
The importance of TRPM2 to CNS function is underscored by
studies implicating TRPM2 in diseases, including stroke/isch-
emia (Jia et al., 2011; Verma et al., 2012; Alim et al., 2013), neu-
rodegenerative diseases (Fonfria et al., 2005; Hermosura et al.,
2008), bipolar disorder (Xu et al., 2006; Jang et al., 2015), and
epilepsy (Katano et al., 2012). These studies suggest that abnor-
mal TRPM2 activity can profoundly influence CNS function and
pathology.Wenow show thatAoligomers can facilitate TRPM2
channel function and that elimination of TRPM2 can reverse
pathological and behavioral deficits observed in the AD mouse
model APP/PS1.
APP/PS1 mice are considered a less aggressive model of A
toxicity, probably reflecting a prodromal phase of AD (Ashe and
Zahs, 2010; Ferretti et al., 2012). Starting at 6 months of age,
APP/PS1 present significant amounts of soluble and plaque-
associated A (Savonenko et al., 2005; Ostapchenko et al.,
2013a). Most transgenic ADmouse models present spatial learn-
ing and memory deficits, as assessed by MWM performance
(Webster et al., 2014) or by Barnes maze (O’Leary and Brown,
2009). However, there are discrepancies for when these deficits
first manifest (Ding et al., 2008; Timmer et al., 2010). Our exper-
iments suggest that the performance of APP/PS1 mice on a bat-
tery of behavioral tasks cannot be distinguished from that of
control mice until reaching 12–15 months of age. At this time,
APP/PS1mice exhibit spatialmemory deficits in bothMWMand
Barnes maze tasks compared with wild-type counterparts. Im-
portantly, elimination of TRPM2 channels ameliorated these def-
icits. The improved performance in both the Barnes maze and
MWM tests with loss of TRPM2 expression in APP/PS1 is not
related to changes in physical activity as bothmouse lines showed
similar levels of activity at all ages tested. Nonetheless, APP/PS1
mice, with or without TRPM2 expressed, showed decreased ac-
tivity by 12–15 months of age, which cor-
roborate previous findings (Ferguson et
al., 2013). Although ablation of TRPM2
channels improved many AD pathology
hallmarks in APP/PS1mice, it did not im-
prove the hypoactivity phenotype. This
hypoactivity could be the result of A-
derived disturbances in muscular func-
tion (Mukhamedyarov et al., 2014).
Indeed, A peptides are elevated in skele-
tal muscles of AD patients (Kuo et al.,
2000), where they have been suggested to
cause membrane depolarization in fibers
by inhibiting the Na/K-ATPase and by
forming membrane pores (Mukhamedy-
arov et al., 2011, 2014). Moreover, A oli-
gomers have been detected in the muscle
fibers of sporadic inclusion body myositis
patients (Nogalska et al., 2010). TRPM2
expression in skeletalmuscles is low (Fon-
fria et al., 2006a), whichmight explain the
lack of improvement in AD-related
hypoactivity.
Although the precise mechanisms
underlying the improvement of spatial
memory deficits by removal of TRPM2
are unknown, they are likely related to
the reduced pathological markers noted
in aged TRPM2//APP/PS1 compared
with APP/PS1 mice. The longitudinal de-
sign of our study precluded biochemical and histological analyses
at time points corresponding with behavioral assays. Neverthe-
less, similar to AD patients (Kim et al., 2000; Andreu et al., 2012),
the brains of 20- to 24-month-old APP/PS1mice present upregu-
lated PDI and increased phosphorylation of eIF2, two molecu-
lar markers of ER stress (Matus et al., 2011; Scheper et al., 2011;
Hetz and Mollereau, 2014). Interestingly, levels of pSer51-eIF2
immunoreactivity in TRPM2/ mice were slightly higher than
in controls, but not due to increased ER stress, as PDI levels
between these two genotypeswere not different. Additionally, 20-
to 24-month-old APP/PS1 mice presented decreased levels of
synaptophysin and increased levels of Iba1, suggesting that their
brains presented synaptic loss and increased microglial activa-
tion. Brains of 20- to 24-month-old APP/PS1 mice lacking
TRPM2 channels (TRPM2//APP/PS1 mice) did not show any
of these deficits, indicating that removal of the Ca2-permeable
oxidative stress sensor TRPM2 can help to normalize the un-
folded protein response and therebymoderate ER stress, synaptic
loss, and inflammation in AD mice. In agreement with this pos-
sibility, in the absence of TRPM2, we did not detect abnormal
expression of other genes that could regulate Ca2 dynamics.
Interestingly, the fact that elimination of TRPM2 does not affect
ER stress responses due to thapsigargin and tunicamycin treat-
ment suggests that TRPM2 elimination does not affect ER
stress responses indiscriminately but rather is selective for A-
mediated effects.
OthermechanismsmayalsobeatplayafterTRPM2removal. For
example, genetic ablation of TRPM2 is associated with increased
phosphorylationofAkt and inactivationof glycogen synthase kinase
GSK3 (Xie et al., 2011; Jang et al., 2015), which was recently found
to be beneficial inADmousemodels (Kazim et al., 2014). This effect
could balance GSK3 activation by PP2B, a phosphatase whose ac-
tivityhasbeendirectly linked toNMDARdysregulationbyA (Sny-
Figure 7. Elimination of TRPM2 in APP/PS1 mice rescues spatial memory deficits in the Barnes maze. Age-dependent impair-
ment of APP/PS1mice performance in Barnesmaze task is rescuedwith TRPM2 removal. A, Errors to reach the target role for 3- to
15-month-oldmice.B, Escape latency for 3- to 15-month oldmice. C,D, On the fifth day,micewere subjected to a 90 s probe trial,
with their spatialmemory recall expressedasnumberof visits to the targethole (C) and thepreference for the targetholeover other
holes during the probe trial (D) for 12-month-old mice. E, F, Similar to C, D, but for 15-month-old mice. Results are expressed as
mean	 SEM. *p 0.05. **p 0.01. ***p 0.001. N for WT 8, N for TRPM2/  8, N for APP/PS1 10, N for
TRPM2//APP/PS1 13.
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der et al., 2005). Therefore, loss of TRPM2
may alter the balance between prosurvival
and prodeath signaling in neurons. Also,
TRPM2 is present inmicroglia, where it can
activate microglia through ROS- and LPS-
mediated signaling, promoting cytokine re-
lease and inflammation (Kraft et al., 2004;
Fonfria et al., 2005, 2006b;Wehrhahn et al.,
2010). AD is also characterized bymicroglia
activation (Kalaria et al., 1996; Dhawan et
al., 2012; Ferretti et al., 2012),whichwecon-
firm in the present study. Genetic deletion
ofTRPM2mitigates this responseproviding
an additional beneficial outcome via re-
duced neuroinflammation. Last, increasing
evidence supports the correlation between
cognitive deficits with the levels of soluble
AOs, both in AD patients and ADmodels
(Lesne´ et al., 2006, 2013; DaRocha-Souto et
al., 2011). Although TRPM2 deletion did
not change the production of A in APP/
PS1 mice, it decreased the amount of small
cell membrane-associated AOs, particu-
larly the trimer and tetramer species. This
may consequently reduce A synaptotoxic-
ity (Figueiredo et al., 2013; Ostapchenko et
al., 2013b).
Several mechanisms through which A
peptides augment TRPM2 function can be
suggested, including oxidative stress, ele-
vated Ca2 and aberrantNMDAR stimula-
tion (Mattson et al., 1999; De Felice et al.,
2007; Malinow, 2012; Um et al., 2012; You
et al., 2012). TRPM2 gating by oxidative/
nitrosative stress occurs via the production
of its agonist, NAD-derived ADPR (Per-
raud et al., 2001).Mitochondria represent a
major cellular store of NAD and ADPR
derived from this source contributes to
TRPM2 activation during oxidative stress
(Perraud et al., 2005). A-induced oxida-
tive/nitrosative stress, associated withmito-
chondrial damage (Mattson et al., 1999),
may represent one source of ADPR. Alter-
natively, ADPR production may be stimu-
lated by DNA repair pathways downstream
of oxidative/nitrosative stress-induced DNA damage (Park et al.,
2014). In addition to ADPR, gating of TRPM2 requires binding of
Ca2/calmodulin to the N terminus of TRPM2 (Tong et al., 2006;
Du et al., 2009). We previously reported that ADPR-promoted
TRPM2activationrequiresCa2 influx throughvoltage-gatedCa2
or NMDAR channels (Olah et al., 2009). Coincidentally, A can
rapidly associate with excitatory synapses in close proximity, if not
directly to NMDARs themselves (Lacor et al., 2004), and provoke
Ca2 dysregulation via aberrant NMDAR stimulation (De Felice et
al., 2007;Shankaret al., 2008;Li et al., 2011;Youetal., 2012).Ofnote,
the actionofApeptides uponNMDARs ismultifacetedwith either
increased (Li et al., 2011; You et al., 2012) or decreased function
(Snyder et al., 2005; Shankar et al., 2007) having been reported.
Reconciling these two opposing functional endpoints, recent evi-
dence suggests that an initial increase in NMDAR function by A
treatment is followed by a loss of surface expression and receptor
function with extended treatment (Um et al., 2012). Importantly,
TRPM2 function can be augmented regardless of the direction of
change inNMDAR function as a consequence of intracellular Ca2
elevations and ROS/RNS production associated with A treatment.
It is important tomention that several distinct geneticmanip-
ulations in mice have shown promising effects on the toxicity of
A peptides or levels of APP metabolites (Lambert et al., 1998;
Ohno et al., 2006; Matus et al., 2011; Ma et al., 2013; Jiang et al.,
2014). Not all manipulations are expected to lead to therapeutic
strategies in humans due to potential experimental limitations.
Of note, independent experiments, published during review of
ourmanuscript, have also shown that TRPM2 in endothelial cells
in the brain vasculature is a target for A peptides (Park et al.,
2014). Particularly, A-induced oxidative stress and DNA dam-
age resulted in overproduction of ADPR, leading to TRPM2 ac-
tivation and calcium imbalance in cerebrovascular cells and
eventually impaired cerebral blood flow. Together with our find-
ings, these results argue that TRPM2 could be a connecting point
Figure 8. Elimination of TRPM2 in APP/PS1mice rescues age-dependent spatialmemory deficits in theMWM.MWM testing of
12-month-old mice (A–D) and 15-month-old mice (E–H ) was performed as described in Materials and Methods. A, E, Learning
curves showing the average latency. B, F, Distance traveled to reach the platform. C, G, Mean swimming speed during the
acquisition of the MWM paradigm. D, H, The percentage of time spent by each genotype swimming on the quadrants during the
probe trial. Data aremean	 SEM. *p 0.05 (vs T). **p 0.01 (vs T). ***p 0.001 (vs T). ****p 0.0001 (vs T). T, Target hole;
O, opposite quadrant; L, left quadrant; R, right quadrant. N values for WT 12, TRPM2/ 10, APP/PS1 11, TRPM2//
APP/PS1 13.
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between oxidative stress and cytotoxic effects in AD. Moreover,
the improvement in molecular markers of AD pathology and
spatial memory deficits in APP/PS1 mice lacking TRPM2 sug-
gests that development of drugs selectively targeting this critical
channel could find use for treating AD. Importantly, we did not
detect any major behavior deficits in mice lacking TRPM2. In
stark contrast to the limited therapeutic index observed for drugs
targeting the NMDAR (Farber et al., 2002), this portends the
possibility of an improved therapeutic index for drugs aimed at
reducing aberrant TRPM2 activation. This is especially impor-
tant given the paucity of available drugs for treating AD patients.
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